Cardiovascular Disease Prevention: 7 Evidence-Based Insights Worth Knowing

Cardiovascular disease prevention is one of the most important and most misunderstood areas of modern medicine. Most people believe that heart disease develops like a slow narrowing of a pipe: plaque builds up gradually, the artery gets tighter, and eventually it closes off. That model is wrong. And the gap between what most patients are told and what the science actually shows has real consequences for how we assess risk, interpret tests, and make treatment decisions.

At RMRM, I approach cardiovascular risk the way I approach every aspect of health optimization: with precision, with the full picture, and without shortcuts. Here is what I think every patient deserves to know about cardiovascular disease prevention.

1. Most Heart Attacks Don’t Come From the Biggest Blockages

The most counterintuitive finding in cardiovascular disease prevention research is this: the plaques most likely to cause a heart attack are not necessarily the ones causing the most obstruction.

Approximately 99% of heart attacks occur because of a ruptured atherosclerotic plaque. When a plaque ruptures, it exposes its contents rich in lipids and inflammatory cells, particularly macrophages to the bloodstream. Those macrophages carry a protein called tissue factor, which triggers the clotting cascade. Within seconds, what was a manageable narrowing becomes a complete blockage.

The critical detail: autopsy studies by researcher Michael Davies showed that many fatal plaque ruptures occurred in arteries with only 30 to 40% blockage. The plaques that kill you are often not the ones your stress test or angiogram flagged as the most significant.

This has profound implications for how we think about screening and risk assessment, and why detecting and treating only the “biggest” lesions misses a large portion of the actual threat.

2. The Calcium Score Tells You Something But Context Is Everything

The coronary artery calcium score (CAC) is one of the most useful tools in cardiovascular disease prevention. It uses low-dose radiation to detect and quantify calcium deposits in the coronary arteries, a marker of plaque burden. But interpreting it correctly requires understanding its limitations.

Calcium is a late-stage feature of plaque development. It is essentially the repair of arterial damage. A calcium score of zero does not mean your arteries are pristine, it means they have not yet reached the point of calcification.

Age changes everything about how to interpret this number. A zero CAC score in a 25-year-old tells us almost nothing. A zero CAC score in a 70-year-old is meaningfully reassuring, their 10-year cardiac risk is low. Conversely, a non-zero calcium score in a 45-year-old is a significant signal that deserves aggressive investigation and management.

The two most clinically useful findings are a young patient who already has calcification, and an older patient who has none. If you fall in the other two quadrants, the CAC score adds limited information.

For determining your 10-year risk, I recommend the MESA 10-Year CHD Risk Calculator, which incorporates both traditional risk factors and CAC score for a more precise estimate.

3. CT Angiography Can See What a Calcium Score Cannot

While the CAC score quantifies calcified plaque, a CT angiogram (CTA) goes further, it shows the anatomy of the arterial wall itself, including soft plaque that has not yet calcified. This means you can identify the early formation of plaque inside the endothelium before it starts to narrow the artery, and before it would appear on a calcium score at all.

The CTA is not appropriate for everyone. In patients with already high calcium scores, the calcification itself obscures the imaging. And it carries a radiation dose of approximately 2 millisieverts, modest compared to annual background radiation but worth factoring into the decision.

For the right patient the CTA provides a level of anatomic detail that changes clinical decisions. It can shift the threshold for initiating statin therapy, PCSK9 inhibitors, or other interventions based on what is actually present in the arterial wall, not just what is symptomatic.

4. Stents for Stable Angina Are Widely Misunderstood

Two landmark trials have fundamentally changed how cardiologists think about stenting for stable coronary artery disease, and the findings have not fully reached patients.

• The COURAGE trial (2007) randomized patients with stable angina to either optimal medical therapy or stents. The result: no difference in heart attack or mortality outcomes. Stents provided symptom relief in some patients but did not change survival.
• The ORBITA trial went further, it used a blinded, sham-controlled design. Patients with known blockages were randomly assigned to either a stent or a sham procedure. Result: even the symptom benefit of stenting was not statistically significant compared to placebo.

This does not mean stents are never appropriate. In a STEMI getting to a catheterization lab within minutes and opening that artery is unambiguously life-saving. There is no debate there. But in stable angina, the evidence is clear: stents are a tool for managing symptoms, not for preventing heart attacks or extending life.

5. Growth Hormone and IGF-1 Have a Surprising Role in Heart Health

One of the most fascinating areas in cardiovascular disease prevention research connects the hormonal axis, specifically growth hormone (GH) and IGF-1, to metabolic and cardiovascular health.

Growth hormone is produced in pulses by the pituitary gland and signals the liver to produce IGF-1, which circulates as the primary biosensor for GH activity. This axis affects far more than muscle growth. It regulates liver fat metabolism, insulin sensitivity, lipid handling, and body composition in ways that directly influence cardiovascular risk.

When GH signaling in the liver is impaired, the result is a dramatic increase in hepatic fat accumulation, a direct driver of the nonalcoholic fatty liver disease now understood to be closely linked to insulin resistance and cardiovascular risk. At the cellular level, GH and insulin are intimately connected: GH essentially acts as a brake on insulin signaling, and disruption of this relationship in the adipocyte has cascading effects on the liver and whole-body glucose metabolism.

The relationship between IGF-1 levels and all-cause mortality follows a U-shaped curve, both very low and very high levels are associated with increased risk. Higher levels appear protective for cardiovascular disease and dementia, while elevated levels associate with increased cancer risk. This complexity is why blanket recommendations about growth hormone supplementation are premature, the biology is nuanced and the trade-offs require careful individualized assessment.

6. Insulin Is an Independent Cardiovascular Risk Factor That Most Panels Don’t Measure

The standard cardiovascular risk panel measures LDL, HDL, triglycerides, and blood pressure. It almost never measures fasting insulin, yet there is good evidence that fasting insulin is an independent risk factor for cardiovascular disease.

The distinction between managing glucose and managing insulin is one of the most important concepts in cardiovascular prevention. Keeping glucose levels in a healthy range through high-insulin strategies manages microvascular complications like kidney disease and neuropathy. But chronically elevated insulin drives macrovascular disease independently of glucose levels.

This is one of the reasons that dietary strategies which lower insulin, even without dramatic changes in standard lipid panels, may have meaningful cardiovascular benefits. It is also why we measure fasting insulin as part of our comprehensive metabolic assessment at RMRM.

7. Primary Prevention Is Still an Art and Precision Matters

Perhaps the most honest and under appreciated truth in cardiovascular disease prevention is that primary prevention is still far more art than science for most patients.

Clinical trials give us information about averages. A trial of 10,000 patients tells us what works for the average person in that cohort. But the patient sitting across from me is not an average. They have a specific family history, a specific lipid pattern, a specific calcium score, a specific insulin sensitivity, and a specific set of risk factors that may not resemble the trial population at all.

The tools we have, like lipids, blood pressure, diabetes status, smoking history, family history, CAC score, CTA, inflammatory markers, insulin and Lp(a) give us a more complete picture than any single trial. The skill is in interpreting them together, understanding the weight of each variable for the individual in front of you, and making treatment decisions that reflect that specific person’s risk profile.

Frequently Asked Questions By Patients

Patient Success Stories

These patient success stories reflect our commitment to treating the root biological causes of knee pain, rather than just masking symptoms. Our mission is to help you restore function, stay active, and age stronger, so you can move better and live better every day.